Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

Bibliography

• Jemal A, Bray F, Center MM, Global Cancer Statistics. CA Cancer J Clin 2011;21:69-90
   Google Scholar
• Available from: http//www.cancer.org (American Cancer Society)
   Google Scholar
• Kumar C, Madison V. AKT crystal structure and AKT-specific inhibitors. Oncogene 2005;24:7493-501
   PubMed Web of Science ®Google Scholar
• Cheng JQ, Lindsley CW, Cheng GZ, The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24(50):7482-92
   Google Scholar
• Kim D, Cheng GZ, Lindsley CW, Targeting phosphatidylinositol-3 kinase/Akt pathway for cancer therapy. Curr Opin In Invest Drugs 2005;6:1250-8
   PubMedGoogle Scholar
• Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003;7:205-28
   PubMedGoogle Scholar
• Zdychova J, Komers R. Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res 2005;54(1):1-16
   Google Scholar
• Mitsiades CS, Mitsiades N, Koutsilieris M, The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004;4:235-56
   PubMed Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62
   PubMed Web of Science ®Google Scholar
• Barnett SF, Bilodeau MT, Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. Curr Topics Med Chem 2005;5(2):109-25
   Google Scholar
• Layton ME, Barnett SF, Bilodeau MT, Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Topics Med Chem 2007;7:1349-63
   Google Scholar
• Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Topics Med Chem 2010;10:458-77
   PubMed Web of Science ®Google Scholar
• Li Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. Exp Opin Ther Patents 2007;17:1077-130
   Web of Science ®Google Scholar
• Laine J, Kunstle G, Obata T, Differential regulation of Akt kinase isoforms by the members of TCL1 oncogene family. J Biol Chem 2002;277:3743-51
   PubMed Web of Science ®Google Scholar
• Datta SR, Brunet A, Greenberg ME. Cell survival: a play in three Akts. Genes Dev 1999;13:2905-27
   PubMed Web of Science ®Google Scholar
• Masure S, Haefner B, Wesselink JJ, Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Euro J Biochem 1999;265:353-60
   Google Scholar
• Cho H, Thorvaldsen JL, Chu QW, Akt1/PKB alpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;276:38349-52
   PubMed Web of Science ®Google Scholar
• Garofalo RS, Orena SJ, Rafidi K, Severe diabetes, age dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003;112:197-208
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK, Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001;292:1728-31
   PubMed Web of Science ®Google Scholar
• Easton RM, Cho H, Roovers K, Role for Akt3/Protein Kinase Bgamma in Attainment of normal brain size. Mol Cell Biol 2005;25(5):1869-78
   Google Scholar
• Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007;35:231-5
   PubMed Web of Science ®Google Scholar
• Degtyarev M, De Maziere A, Orr C, Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008;183:101-16
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Zhao Z, Duggan ME, Allosteric Akt (PKB) kinase inhibitors. Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 2005;15:761-4
   PubMed Web of Science ®Google Scholar
• Defeo-Jones D, Barnett SF, Fu S, Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005;4(2):271-9
   Google Scholar
• Murray AJ. Pharmacological PKA inhibition: all may not be what it seems. Sci Signal 2008;1:1-6
   Google Scholar
• Milburn CC, Deak M, Kelly SM, Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 2003;375:531-8
   PubMed Web of Science ®Google Scholar
• Yang J, Cron P, Good VM, Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002;9:940-4
   PubMedGoogle Scholar
• Yang J, Cron P, Thompson V, Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 2002;9:1227-40
   PubMed Web of Science ®Google Scholar
• Garcia Echeverria C, Traxler P, Evans DB. ATP site-directed competitive and irreversible inhibitors of protein kinases. Medici Res Rev 2000;20:28-57
   Google Scholar
• Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Cur Biol 1997;7:261-9
   PubMed Web of Science ®Google Scholar
• Stokoe D, Stephens LR, Copeland T, Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997;277:567-70
   PubMed Web of Science ®Google Scholar
• Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18(1):77-82
   Google Scholar
• Wetzker R, Rommel C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 2004;10(16):1915-22
   Google Scholar
• Chen KQ, Iribarren P, Gong WH, The Essential role of Phosphoinositide 3-kinases (PI3Ks). Mol Immunol 2005;2(4):241-52
   Google Scholar
• Simpson L, Parsons R. PTEN: life as a tumor suppressor. Experi Cell Res 2001;264:29-41
   PubMed Web of Science ®Google Scholar
• Chow L, Lionel ML, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett 2006;241(2):184-96
   Google Scholar
• Hede K. PTEN takes center stage in cancer stem cell research, works as tumor suppressor. J Natl Cancer Inst 2006;98(12):808-9
   Google Scholar
• Cully M, You H, Levine AJ, Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6(3):184-92
   PubMed Web of Science ®Google Scholar
• Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003;13:478-83
   PubMed Web of Science ®Google Scholar
• Bayascas JR, Leslie NR, Parsons R, Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/- mice. Curr Biol 2005;15:1839-46
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105(7):2640-53
   Google Scholar
• Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2005;6(1):105-13
   PubMedGoogle Scholar
• Cappuzzo F, Finocchiaro G, Metro G, Clinical experience with gefitinib:an update. Crit Rev Oncol Hematol 2006;58:31-45
   PubMed Web of Science ®Google Scholar
• Tang PA, Tsao M-S, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006;7(2):177-93
   Google Scholar
• Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of Her2-positive metastatic and early-stage breast cancer. Drugs 2006;66(4):449-75
   Google Scholar
• Cappuzzo F, Marrini E, Ceresoli GL, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2004;96:1133-41
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer. J Nat Cancer Inst 2005;97(9):643-55
   Google Scholar
• Suzuki A, de la Pompa JL, Stambolic V, High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pesce B, Cordon-Cardo C, Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-55
   PubMed Web of Science ®Google Scholar
• Podsypanina K, Ellenson LH, Nemes A, Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8
   PubMed Web of Science ®Google Scholar
• Bayascas J, Leslie J, Parsons N, Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN mice. Curr Biol 2005;15(20):1839-46
   Google Scholar
• Chen M-L, Xu P-Z, Peng X, The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 2006;20:1569-74
   PubMed Web of Science ®Google Scholar
• Pal KS, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19:1355-66
   PubMed Web of Science ®Google Scholar
• La Cour CM, Salles M-J, Pasteau V, Signaling pathways leading to phosphorylation of Akt and GSK-3beta by activation of cloned human and rat cerebral D2 and D3 receptors. Mol Pharm 2011;79:91-105
   Google Scholar
• Dwyer DS, Weeks KR, Aamodt EJ. Drug discovery based on genetic and metabolic findings in schizophrenia. Expert Rev Clin Pharmacol 2008;1:773-89
   PubMedGoogle Scholar
• Lu XH, Dweyer DS. Second generation antipsychotic drugs olanzapine, quetiapine and clozapine enhance neurite outgrowth in PC12 cells via the PI3K/Akt, ERK and pertussis toxin-sensitive pathways. J Mol Neurosci 2005;27:43-64
   PubMed Web of Science ®Google Scholar
• Weeks KR, Dwyer DS, Aamodt EJ. Antipsychotic drugs activate the C. elegans Akt pathway via the DAE-2 insulin/IGF-1 receptor. ACS Chem Neurosci 2010;1:463-73
   PubMedGoogle Scholar
• Emamian E, Hall D, Birnbaum M, Convergent evidence for impaired AKT-GSK3beta signaling in schizophrenia. Nat Genet 2004;36:131-7
   PubMed Web of Science ®Google Scholar
• Chubb JE, Bradshaw NJ, Soares DC, The DISC1 locus in psychiatric illness. Mol Psychiatry 2008;13:36-64
   PubMed Web of Science ®Google Scholar
• Kim JY, Duan X, Liu C, DISC1 regulates new neuronal development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 2009;63:761-73
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Shipe WD, Wolkenberg SE, Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Topics Med Chem 2006;8:771-84
   Google Scholar
• Siuta MA, Robertson SD, Kocalis H, Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice'. PLoS Biol 2010;8:e1000393-401
   Web of Science ®Google Scholar
• Robertson SD, Owens AW, Matthies HJG, Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis J Neurosci 2010;30:11305-16
   Google Scholar
• Speed NR, Matthies HJG, Kennedy JP, Akt dependent and isoform specific regulation of the dopamine transporter cell surface expression' ACS Chem Neurosci 2010;1:476-481
   Google Scholar
• Gills JJ, Dennis PA. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin Invest Drugs 2004;13:787-97
   PubMed Web of Science ®Google Scholar
• Meuillet EJ, Mahadevan D, Vankayalapati H, Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2003;2:389-99
   PubMed Web of Science ®Google Scholar
• Powis G, Aksoy IA, Melder DC, D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth. Cancer Chemother Pharmacol 1991;29:95-104
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Kiddle JJ, Frew T, Synthesis and biology of 1D-3-deoxyphosphatidylinositol: a putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. J Med Chem 1995;38:1053-6
   PubMed Web of Science ®Google Scholar
• Qiao L, Nan F, Kunkel M, 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J Med Chem 1998;41:3303-6
   PubMed Web of Science ®Google Scholar
• Castillo SS, Brognard J, Petukhov PA, Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004;64:2782-92
   PubMedGoogle Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009;11:102-10
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62
   PubMed Web of Science ®Google Scholar
• Vink SR, Schellens JHM, Beijnen JH, Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 2006;80:207-13
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Leleu X, Rubin N, Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). Meeting Abstracts. J Clin Oncol 2008;26(15 Suppl):8546
   Google Scholar
• NCT01097018: a Phase III randomized study to assess the efficacy and safety of perifosine plus capecitabine versus placebo plus capecitabine in patients with refractory advanced colorectal cancer. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01097018?term= NCT01097018&rank=1 [Last accessed 1 September 2010]
   Google Scholar
• Zentaris GMBH. WO2004012744; 2004
   Google Scholar
• Moses SA, Ali MA, Zuohe S, In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/Akt. Cancer Res 2009;69:5073-81
   Google Scholar
• Meuillet EJ, Zuohe S, Lemos R, Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphotidylinostitide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010;9:706-17
   PubMed Web of Science ®Google Scholar
• Ahad AM, Zuohe S, Du-Cuny L, Devleopment of sulfonamide Akt PH domain inhibitors. Bioorg Med Chem Lett 2011;19:2046-54
   Google Scholar
• University of Texas; University of Arizona. WO2009129267; 2009
   Google Scholar
• PHusis Therapeutics. WO2011032169; 2011
   Google Scholar
• Rebecchi MJ, Scarlata S. PLeckstrin homology domains: a common fold with diverse functions. Annu Rev Biophys Biomol Struct 1998;27:503-28
   PubMedGoogle Scholar
• Workman P, Clark PA, Guillard S, Druggin the PI3 kinome. Nat Biotechnol 2006;24:794-6
   PubMed Web of Science ®Google Scholar
• Li Q, Zhu GD. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2002;2:939-71
   PubMedGoogle Scholar
• Breitenlechner CB, Wegge T, Berillon L, Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 2004;47:1375-90
   PubMed Web of Science ®Google Scholar
• Chijiwa T, Mishima A, Hagiwara M, Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990;265:5267-72
   PubMed Web of Science ®Google Scholar
• Reuveni H, Livnah N, Geiger T, Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 2002;41:10304-14
   PubMed Web of Science ®Google Scholar
• Li Q, Li T, Zhu GD, Discovery of trans-3,4″-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: synthesis and biological evalutions. Bioorg Med Chem Lett 2006;16:1679-85
   PubMedGoogle Scholar
• Li Q, Woods KW, Thomas S, Synthesis and strucutre-activity relationship of trans-3,4″-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorg Med Chem Lett 2006;16:2000-7
   PubMedGoogle Scholar
• Thomas SA, Li T, Woods KW, Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Bioorg Med Chem Lett 2006;16:3740-4
   PubMedGoogle Scholar
• Zhu G-D, Gandhi VB, Gong J, Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg Med Chem Lett 2006;16:3424-9
   PubMedGoogle Scholar
• Woods KW, Fischer JP, Claiborne A, Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg Med Chem Lett 2006;14:6832-46
   Google Scholar
• Luo Y, Shoemaker AR, Liu X, Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005;4:977-86
   PubMed Web of Science ®Google Scholar
• Zhou G-D, Gandhi VB, Gong J, Synthesis of potent, selective and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypertension. J Med Chem 2007;50:2990-3003
   Google Scholar
• Lin X, Murray JM, Rico AC, Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett 2006;16:4163-8
   PubMedGoogle Scholar
• Seefeld MA, Rouse MB, McNulty KC, Discovery of 5-pyrrolpyridinyl-2-thiopenecarboxamides as potent Akt inhibitors'. Bioorg Med Chem Lett 2009;19:2244-8
   Google Scholar
• Heerding DA, Rhodes N, Leber JD, Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{(3S)-3-piperidinylmethyl]oxy}-1H-imidazo4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase'. J Med Chem 2008;51:5663-79
   PubMed Web of Science ®Google Scholar
• Rouse MB, Seefeld MA, Leber JD, Aminofurazans as potent inhibitors of AKT kinase. Bioorg Med Chem Lett 2009;19:1508-11
   PubMed Web of Science ®Google Scholar
• Altomare DA, Zhang L, Deng J, GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res 2010;16:486-96
   PubMed Web of Science ®Google Scholar
• NCT00493818: open-label study to investigate the safety, tolerability, PK, and pharmacodynamics of the AKT inhibitor GSK690693. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00493818
   Google Scholar
• LoRusso P, Hurwitz H, Chiorean E, AKT inhibitor GSK690693: preliminary results from the first time in human study. 1 Annual Meeting. AACR Meeting Abstracts; 2008. p. LB-68
   Google Scholar
• NCT00920257: a phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the oral AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas. Bethesda, MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00920257?term=NCT00920257
   Google Scholar
• Lippa B, Pan G, Corbett M, Synthesis and structure based optimization of novel Akt inhibitors. Bioorg Med Chem Lett 2008;18:3359-63
   Google Scholar
• Freeman-Cook KD, Autyr C, Borzillo G, Design of selective ATP-competitive inhibitors of Akt. J Med Chem 2010;53:4615-22
   PubMed Web of Science ®Google Scholar
• Ko JH, Yeon SW, Ryu JS, Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg Med Chem Lett 2006;16:6001-5
   PubMed Web of Science ®Google Scholar
• Blake JF, Kallan NC, Xiao D, Discovery of pyrrolopyrimidine inhibitors of Akt. Bioorg Med Chem Lett 2010; 20:5607-12
   Google Scholar
• Lin H, Yamashita DS, Xie R, Tetrasubstituted pyridines as potent and selective Akt inhibitors: reduced CYP450 and hERG inhibition of aminopyridines. Bioorg Med Chem Lett 2010;20:648-88
   Google Scholar
• Zeng Q, Allen JG, Bourbeau MP, Azole-based inhibitors of Akt/PKB for the treatment of cancer. Bioorg Med Chem Lett 2010;20:1559-64
   PubMed Web of Science ®Google Scholar
• Zeng Q, Bourbeau MP, Wohlheiter GE, 2-Aminothiadiazole inhibitors of Akt1 as potential cancer therapeutics. Bioorg Med Chem Lett 2010;20:1652-6
   Google Scholar
• Xu R, Banka A, Blake F, Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA. Bioorg Med Chem Lett 2011;21:2335-40
   Google Scholar
• Kallan NC, Spencer KL, Blake JF, Discovery and SAR of spirochromane Akt inhibitors. Bioorg Med Chem Lett 2011;21:2410-14
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. US7449477; 2008
   Google Scholar
• Eli Lilly and Co. US7414063; 2008
   Google Scholar
• Amgen, Inc. WO20090298836; 2009
   Google Scholar
• Amgen, Inc. WO20090275592; 2009
   Google Scholar
• Astra Zeneca AB. WO20090163524; 2009
   Google Scholar
• SmithKline Beecham Corp. WO20100137338; 2010
   Google Scholar
• SmithKline Beecham Corp. WO20100267759; 2010
   Google Scholar
• Imperial College Innovations, Ltd. WO20080039527; 2008
   Google Scholar
• Eli Lilly & Co. WO20090221633; 2009
   Google Scholar
• SmithKline Beecham Corp. WO20100056523; 2010
   Google Scholar
• SmithKline Beecham Corp. WO20090209607; 2009
   Google Scholar
• St. Jude's Children Research Hospital. WO20060241108; 2006
   Google Scholar
• SmithKline Beecham Corp. WO20080318947; 2008
   Google Scholar
• St. Jude's Children Research Hospital. WO2006094207; 2006
   Google Scholar
• Array Biopharma. WO2008006025; 2008
   Google Scholar
• Array Biopharma. WO2008006032; 2008
   Google Scholar
• Array Biopharma. WO2009006569; 2009
   Google Scholar
• Array Biopharma. WO2008006039; 2008
   Google Scholar
• Array Biopharma. WO2008006040; 2008
   Google Scholar
• Array Biopharma. WO2009006567; 2009
   Google Scholar
• Array Biopharma. WO2009089453; 2009
   Google Scholar
• Exelixis. WO2005117909; 2005
   Google Scholar
• Exelixis. WO2006071819; 2005
   Google Scholar
• Vertex. WO2005030776; 2005
   Google Scholar
• Vertex. US7041687; 2006
   Google Scholar
• Vertex. WO2005039564; 2005
   Google Scholar
• Astex. WO2005061463; 2005; WO2006136823; 2006; WO2006136830; 2006; GB2427406; 2006
   Google Scholar
• Aventis Pharma. US0248884; 2004; WO2006010641; 2006; WO2006010642; 2006; WO2006010643; 2006
   Google Scholar
• NCT00460278: a phase 1 dose-escalation study of the safety and pharmacokinetics of XL418 administered orally daily to subjects with solid tumors. Available from: http://www.clinicaltrials.gov
   Google Scholar
• Breitenlechner CB, Wegge T, Berillon L, Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 2004;47:1375-90
   PubMed Web of Science ®Google Scholar
• Zinda MJ, Johnson MA, Paul JD, AKT-1,-2, and-3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001;7(8):2475-9
   Google Scholar
• Hsu JH, Shi Y, Hu L, Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 2002;21:1391-400
   PubMed Web of Science ®Google Scholar
• Brognard J, Clark AS, Ni Y, Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001:61:3986-97
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Sun H, Brognard J, Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 2003;125:1144-5
   PubMed Web of Science ®Google Scholar
• Graff JR. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 2002;6:103-13
   PubMedGoogle Scholar
• Yang ZZ, Tschopp O, Baudry A, Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004;32:350-4
   PubMed Web of Science ®Google Scholar
• Barnett SF, Defeo-Jones D, Fu S, Identification and characterization of pleckstrin homology domain dependent and isozyme specific Akt inhibitors. Biochem J 2004;385:399-408
   Google Scholar
• Calleja V, Laguerre M, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: Structural mechanism for allosteric inhibition. PLoS Biol 2009;7:189-200
   Google Scholar
• Wu WI, Voegtil WC, Sturgis HL, Crystal structure of humanAKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. PLoS One 2010;5:e12913
   PubMed Web of Science ®Google Scholar
• Okuzumi T, Fielder D, Zhang C, Inhibitor hijacking of Akt activation. Nat Chem Bio 2009;5:484-93
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan B, Fosbrink M, Radhar M, Live cell molecular analysis of Akt reveals roles for activation loop phosphorylation. J Biol Chem 2007;282:36634-41
   PubMedGoogle Scholar
• Zhao Z, Duggan ME, Barnett SF, Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 2005;15:905-9
   PubMed Web of Science ®Google Scholar
• Zhao Z, Robinson RG, Barnett SF, Development of potent, allosteric Akt1 and Akt2 dual inhibitors with improved physical properties and cell activity. Bioorg Med Chem Lett 2008;18:49-53
   PubMed Web of Science ®Google Scholar
• Bilodeau MT, Balitza AE, Hoffman JM, Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 2008;18:3178-82
   PubMedGoogle Scholar
• Wu Z, Robinson RG, Fu S, Rapid assembly of diverse and potent allosteric Akt inhibitors. Bioorg Med Chem Lett 2008;18:2211-14
   PubMedGoogle Scholar
• Wu Z, Hartnett JC, Neilson LA, Development of pyridopyrimidines as potent Akt1/2 inhibitors. Bioorg Med Chem Lett 2008;18:1274-9
   Google Scholar
• Sui T, Liang J, Arruda J, Discovery of potent and cell-active allosteric dual Akt1 and 2 inhibitors'. Bioorg Med Chem Lett 2008;18:4186-90
   Google Scholar
• Sui T, Li Y, Nagasawa J, The design and synthesis of potent and cell-active allosteric dual Akt1 and 2 inhibitors devoid of hERG activity. Bioorg Med Chem Lett 2008;18:4191-4
   Google Scholar
• Li Y, Liang J, Sui T, Allosteric inhibitors of Akt 1 and Akt2: discovery of 1,2,4]triazolo3,4-f]1,6]naphthyridines with potent and balanced activity. Bioorg Med Chem Lett 2009;19:834-6
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, An allosteric Akt inhibitor, MK-2206 enhanced anti-tumor efficacy by standard of care agents or molecular targeted drugs in vitro and in vivo. AACR Meeting Abstracts; 2009. p. 3707
   Google Scholar
• Yap TA, Patnaik A, Fearen I, First-in-class Phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly(QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. Meeting Abstracts. J Clin Oncol 2010;28(15 Suppl):3009
   Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-67
   PubMed Web of Science ®Google Scholar
• Lu W, Defeo-Jones D, Davis LJ, In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor. AACR Meeting Abstracts; 2009. p. 3714
   Google Scholar
• Johnson LA. AstraZeneca, Merck collaborate on cancer treatment. AP Business Wire; 1 June 2009
   Google Scholar
• Merck. US7034026; 2006
   Google Scholar
• Merck. US7273869; 2007
   Google Scholar
• Merck. US7223738; 2007
   Google Scholar
• Merck. US7638530; 2009
   Google Scholar
• Merck. US7579355; 2009
   Google Scholar
• Merck. US7576209; 2009
   Google Scholar
• Merck. US7544677; 2009
   Google Scholar
• Merck. US7524850; 2009
   Google Scholar
• Merck. US7399764; 2008
   Google Scholar
• Merck. US7396832; 2008
   Google Scholar
• Merck. US7414055; 2008
   Google Scholar
• Merck. US7304063; 2008
   Google Scholar
• Merck. US7750151; 2010
   Google Scholar
• Merck. US7655649; 2010
   Google Scholar
• Merck. US7589068; 2009
   Google Scholar
• Merck. US6960584; 2005
   Google Scholar
• Merck: US7098208; 2006
   Google Scholar
• Merck. US6958334; 2005
   Google Scholar
• Bayer Schering PharmaWO20090091824; 2009
   Google Scholar
• Merck. WO20100222321; 2010
   Google Scholar
• Merck. WO20100075970; 2010
   Google Scholar
• Merck. WO20090062327; 2009
   Google Scholar
• Merck. WO20090253734; 2009
   Google Scholar
• Merck. WO20100022573; 2010
   Google Scholar
• Imclone. WO2005007099; 2005
   Google Scholar
• Schramm KH, Townsend LB. The synthesis of 6-amino-4-methyl-8-(beta-D-ribofuranosyl)-(4H,8H)-pyrrolo-4,3,2-de]pyrimido4,5-c]pyridazine, a new tricyclic nucleotide. Tetrahedron Lett 1971;49:4757-60
   Google Scholar
• Yang L, Dan HC, Sun M, Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumour activity in cancer cells overexpressing Akt. Cancer Res 2004;64:4394-9
   PubMed Web of Science ®Google Scholar
• Schweinsberg PD, Smith RG, Loo TL. Identification of the metabolites of an antitumour tricyclic nucleoside (NSC-154020). Biochem Pharmacol 1981;30:2521-6
   PubMed Web of Science ®Google Scholar
• Mittelman A, Casper ES, Godwin TA, Phase I study of tricyclic nucleoside phosphate. Cancer Treat Rep 1983;67:159-62
   PubMedGoogle Scholar
• Feun LG, Savaraj N, Bodey GP, Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res 1984;44:3608-12
   PubMed Web of Science ®Google Scholar
• Schilcher RB, Haas CD, Samson MK, Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen. Cancer Res 1986;46:3147-51
   PubMed Web of Science ®Google Scholar
• Hoffman K, Holmes FA, Fraschini G, Phase I – II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 1996;37:254-8
   PubMed Web of Science ®Google Scholar
• Dieterle A, Orth R, Daubrawa M, The Akt inhibitor triciribine sensitizesd prostate carcinoma cells to TRAIL-induced apopotsis. Int J Cancer 2009;125:932-41
   PubMed Web of Science ®Google Scholar
• University of South Florida. US0028339; 2010
   Google Scholar
• University of South Florida. US0008327; 2011
   Google Scholar
• University of South Florida. US0113381; 2010
   Google Scholar
• NCT00363454: Phase I Study of Triciribine Phosphae Monohydrate (TCN-PM, VD-002) in Adult Subjects with Metastatic Cancer. Clinical trials.gov, 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00363454
   Google Scholar
• NCT00642031: Triciribine Phosphae Monohydrate (TCN-PM, VD-002) in Adult Patients with Advanced Hematologic Malignancies. Clinical trials.gov, 2011. Available from: http://clinicaltrials.gov/ct2/show/NCT00642031
   Google Scholar
• Nuclea Biotechnologies LLC. WO20100092473; 2010
   Google Scholar
• Nastech Pharmaceuticals. WO20080293136; 2008
   Google Scholar
• Isis Pharmaceuticals. US5958773; 1999
   Google Scholar
• Isis Pharmaceuticals. US6043090; 2000
   Google Scholar
• Isis Pharmaceuticals. US6187586; 2001
   Google Scholar
• Yoon H, Kim DJ, Ahn EH, Antitumor activity of a novel antisense oligonucleotide against Akt1. J Cell Biochem 2009;108:832-8
   PubMed Web of Science ®Google Scholar
• US Patent Granted for Rexahn Pharmaceuticals Leading Cancer Candidate. Rockville, MD: rexahn pharmaceuticals press release, 6 November 2006. Available from: http://www.rexahn.com/cms/index.php/2006/11/us-patent-grantedfor-rexahn-pharmaceuticals-leadingcancer-candidate-2
   Google Scholar
• Marshall J, Posey J, Hwang J, A Phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer. Meeting Abstracts. J Clin Oncol 2007;25(18 Suppl):3564
   Google Scholar
• NCT01028495: a safety and efficacy study of RX-0201 plus gemcitabine in metastatic pancreatic cancer. Bethesda,MD: US National Institutes of Health, Clinical trials.gov, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01028495
   Google Scholar